Welcome to Mediso
Please select your region:
North America
Canada
USA
Europe
Austria
Belgium
France
Germany
Hungary
Ireland
Poland
United Kingdom
Rest of the World
Global
Please select your language:
English
Magyar
Deutsch
Polski
Espanol
Français
Go
Cryogen-free MRI Magnet Tech Transfer
2025.05.09.
Mediso is pleased to announce the successful completion of the first phase of a strategic technology transfer agreement with Superconducting Systems Inc.
Mediso is pleased to announce the successful completion of the first phase of a strategic technology transfer agreement with Superconducting Systems Inc. (SSI), a fully owned subsidiary of IMRIS. This agreement marks a significant milestone in Mediso’s long-term commitment to vertical integration and innovation in the field of MRI system development.
Over the past decade, Mediso used SSI’s fully cryogen-free superconducting magnets, resulting in the launch of the widely adopted nanoScan® 3T and 7T MRI systems. These pioneering systems have set a new standard in preclinical MRI by eliminating the need for liquid helium and other cryogens.
W ith the initial phase of the transfer now complete, Mediso is actively ramping up its European magnet manufacturing capabilities. Full-scale production is expected to be operational by the end of the year, incorporating Mediso’s robust quality management systems into serial production processes.
“This is the last piece of the puzzle for Mediso for a complete vertical integration of its MRI products and the way forward in developing new MRI systems, up to 9.4T” said Gergo Bagamery, Director of Preclinical Product Development at Mediso. “Owning the magnet technology allows us to create novel designs across a range of field strengths and bore sizes with unmatched flexibility.”
The transferred technology grants Mediso access to SSI’s foundational intellectual property and patented technologies for the field preclinical MRI, enabling the development of new conduction-cooled superconducting magnets with bore sizes optimized up to 9.4T.